Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: Sub‐analysis of a randomized controlled study
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16198 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Kiichi Hirayama und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition and Metabolic Medicine, Center for Preventive Medical Science, Chiba University, Chiba, Japan. Hauptthemen laut MEDLINE: Metformin, Glucosides, Liver Cirrhosis, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Astellas Pharma.
Abstract (Originalsprache)
Aims
To compare the effects of ipragliflozin, a sodium‐dependent glucose transporter‐2 inhibitor, and those of metformin on the visceral fat area (VFA), a prospective, multi‐centre, open‐label, blinded‐endpoint, randomized, controlled study was undertaken. The generated data were used to examine the effects of ipragliflozin and metformin on indices of hepatic steatosis and liver fibrosis. Materials and Methods In total, 103 Japanese patients with type‐2 diabetes (T2D), body mass index (BMI) of ≥22 kg/m 2 and glycated haemoglobin level of 7%–10% were randomly administered ipragliflozin 50 mg or metformin 1000 mg for 24 weeks. Various parameters, including hepatic steatosis indices, fatty liver index (FLI), hepatic steatosis index (HSI), non‐alcoholic fatty liver disease‐liver fat score (NAFLD‐LFS), liver fibrosis indices, AST to platelet ratio index (APRI) and fibrosis‐4 (FIB‐4) index, were compared in the sub‐analyses. The correlations between changes in each index and VFA were evaluated.
Results
At baseline, patients demonstrated moderate hepatic steatosis, with FLI scores of 52.9 ± 26.6 and 57.8 ± 29.0 in the ipragliflozin and metformin groups, respectively. At 24 weeks, compared with metformin, ipragliflozin showed improvements in hepatic steatosis indices: FLI (−9.24 ± 10.7 vs. −3.45 ± 11.8, p = 0.013), HSI (−1.45 ± 2.32 vs. −0.45 ± 1.87, p = 0.021), NAFLD‐LFS (−0.70 ± 1.46 vs. −0.04 ± 0.98, p = 0.011) and liver fibrosis index: APRI (−0.110 ± 0.323 vs. 0.033 ± 0.181, p = 0.010). In the ipragliflozin group, changes in FLI and HSI were correlated with VFA reduction ( r = 0.340, p = 0.024; r = 0.367, p = 0.011, respectively).
Conclusions
Compared with metformin, ipragliflozin improved multiple hepatic steatosis and liver fibrosis indices, suggesting that ipragliflozin exerts potential hepatoprotective effects in early‐stage liver disease associated with T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutrition and Metabolic Medicine, Center for Preventive Medical Science, Chiba University, Chiba, Japan.
- Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kimitsu Chuo Hospital, Kisarazu, Japan.
- Department of Internal Medicine, Minami-Boso City Tomiyama National Health Insurance Hospital, Minami-Boso, Japan.
- Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan.
- Department of Medicine, Division of Diabetes, Metabolism and Endocrinology, Chiba University Hospital, Chiba, Japan.
- Clinical Research Center, Chiba University Hospital, Chiba, Japan.
ORCID-Profile: Masaya Koshizaka, Ryoichi Ishibashi, Koutaro Yokote
Förderung
- Astellas Pharma
Zitieren
APA
Hirayama, K., Koshizaka, M., Ishibashi, R., Shoji, M., Horikoshi, T., Sakurai, K., Yokote, K., & PRIME‐V Study Group (2025). Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: Sub‐analysis of a randomized controlled study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16198
Vancouver
Hirayama K, Koshizaka M, Ishibashi R, Shoji M, Horikoshi T, Sakurai K, et al. Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: Sub‐analysis of a randomized controlled study. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16198
BibTeX
@article{Hirayama2025,
author = {Hirayama, Kiichi and Koshizaka, Masaya and Ishibashi, Ryoichi and Shoji, Mayumi and Horikoshi, Takuro and Sakurai, Kenichi and Yokote, Koutaro and PRIME‐V Study Group, PRIME‐V Study Group},
title = {Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: Sub‐analysis of a randomized controlled study},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16198}
}
EUVIMED